Actavis (Teva) is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $6.0B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Actavis (Teva)'s stage | 2025 brand sales |
|---|---|---|---|---|---|
| Xtandi | Astellas / Pfizer | Generic | 2027 | FDA-approved capsules (2021 to 2024), not marketed | ≈$6.0B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Actavis (Teva)'s share of it.